TY  - JOUR
TI  - Successful Treatment of Refractory Graft-Versus-
Host Disease with Ruxolitinib in a Child after
Autologous Stem Cell Transplantation
AB  - Autologous hematopoietic stem cell transplantation (AHSCT) is an increasingly used curative treatment for some solid tumors in children.
Instead of allogeneic transplantation, the risk of developing graft-versus-host disease (GvHD) is much lower after AHSCT. Although the clinical
findings of auto-GVHD are mild and self-limited in most cases, rare cases may be severe and need intensive immunosuppressive treatment.
Here, we present a case who underwent autologous HSCT due to relapsed neuroblastoma, developed steroid-refractory GvHD after AHSCT, and
achieved remission using ruxolitinib. A 12 years old female patient was diagnosed with relapsed neuroblastoma. After metaiodobenzylguanidine
treatment, AHSCT was performed, and the status of the disease was a very good partial response at the time of transplantation. Our patient was
diagnosed with severe and steroid-refractory GvHD with skin involvement after AHSCT. We used ruxolitinib with extracorporeal photopheresis
because of the essential side effects of the other drugs and got a very good response. Over the following five months, there was no recurrence
of GvHD. She was in complete remission of neuroblastoma after two years of AHSCT. It is crucial to keep in mind that GvHD may develop after
AHSCT. Ruxolitinib is an effective treatment for GvHD also after AHSCT. Further studies and case reports are needed to understand the disease’s
pathogenesis and regulate appropriate treatment.
AU  - KOÇ, Ahmet
AU  - ŞENAY, Emel
AU  - TOKUÇ, Ayşe Gülnur
AU  - tufan taş, burcu
AU  - DOGRU, OMER
AU  - EKER, Nurşah
DO  - 10.4274/jpr.galenos.2022.69335
PY  - 2022
JO  - The Journal of Pediatric Research
VL  - 9
IS  - 2
SN  - 2147-9445
SP  - 197
EP  - 200
DB  - TRDizin
UR  - http://search/yayin/detay/519192
ER  -